CXC chemokine ligand 12/Stromal cell-derived factor-1 regulates cell adhesion in human colon cancer cells by induction of intercellular adhesion molecule-1

Shui-Yi Tung1, Shun-Fu Chang2, Ming-Hui Chou3, Wen-Shih Huang4, Yung-Yu Hsieh1, Chien-Heng Shen1, Hsing-Chun Kuo5 and Cheng-Nan Chen3*

Abstract

Background: The CXC chemokine ligand 12 (CXCL12)/stromal cell-derived factor-1 (SDF-1) and CXC receptor 4 (CXCR4) axis is involved in human colorectal cancer (CRC) carcinogenesis and can promote the progression of CRC. Interaction between CRC cells and endothelium is a key event in tumor progression. The aim of this study was to investigate the effect of SDF-1 on the adhesion of CRC cells.

Methods: Human CRC DLD-1 cells were used to study the effect of SDF-1 on intercellular adhesion molecule-1 (ICAM-1) expression and cell adhesion to endothelium.

Results: SDF-1 treatment induced adhesion of DLD-1 cells to the endothelium and increased the expression level of the ICAM-1. Inhibition of ICAM-1 by small interfering RNA (siRNA) and neutralizing antibody inhibited SDF-1-induced cell adhesion. By using specific inhibitors and short hairpin RNA (shRNA), we demonstrated that the activation of ERK, JNK and p38 pathways is critical for SDF-1-induced ICAM-1 expression and cell adhesion. Promoter activity and transcription factor ELISA assays showed that SDF-1 increased Sp1-, C/EBP-β- and NF-κB-DNA binding activities in DLD-1 cells. Inhibition of Sp1, C/EBP-β and NF-κB activations by specific siRNA blocked the SDF-1-induced ICAM-1 promoter activity and expression. The effect of SDF-1 on cell adhesion was mediated by the CXCR4.

Conclusion: Our findings support the hypothesis that ICAM-1 up-regulation stimulated by SDF-1 may play an active role in CRC cell adhesion.

Keywords: Colorectal cancer, Stromal cell-derived factor-1, Intercellular adhesion molecule-1, Cell adhesion, Transcriptional regulation

Background

Colorectal cancer (CRC) is one of the most common malignancies and is the fourth leading cause of cancer death worldwide. Death due to colorectal cancer usually results from metastatic spread of cancer cells [1]. Chemokines play a pivotal role in tumor progression because they may affect growth, adhesion and metastasis of tumor cells [2,3]. CXC chemokine ligand 12 (CXCL12)/Stromal cell-derived factor (SDF-1) is a member of the CXC chemokine family, which plays an important role in chemotaxis, haematopoiesis, angiogenesis and tumor spread and metastasis [4,5]. SDF-1 is expressed in several cancer cells and is involved in tumor cell migration and metastasis [6,7]. Several studies have indicated that CRC cells promoted their survival and migration to distant tissues by interaction between SDF-1 and its specific receptor, CXC receptor 4 (CXCR4). The higher expression of CXCR4 in tumor tissue correlates with poor prognosis and poor survival in CRC patients [8,9].

* Correspondence: cnchen@mail.nyu.edu.tw
3Department of Biochemical Science and Technology, National Chiayi University, Chiayi, Taiwan

Full list of author information is available at the end of the article

© 2012 Tung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Tumor cell adhesion is not only associated in tumor cell detachment from the primary carcinoma, but is also involved in cell attachment to distant tissue [10]. The maintenance and promotion of cell adhesion are particularly important processes in CRC progression and metastasis. The intercellular adhesion molecule-1 (ICAM-1) is a member of the immunoglobulin (Ig) gene superfamily of adhesion molecules. It is involved in cancer cell adhesion and in the immune responses of tumors [11,12]. The interaction between ICAM-1 and its specific ligand may facilitate adhesion of cancer cells to the vascular endothelium and subsequently in the promotion of metastasis. It has been reported that the serum level of soluble (s)ICAM-1 is elevated in patients with cancers [13]. High serum levels of sICAM-1 have been shown to be correlated with tumor progression in cases of CRC and associated with liver metastasis [14,15]. Normal colon tissues do not express ICAM-1, but this adhesion molecule can be up-regulated on malignant transformation [16]. Several studies also suggest that ICAM-1 plays an important role in CRC progression and metastasis [17-19]. It has been demonstrated that SDF-1 effectively induced the expression of urokinase plasminogen activator in CRC cells [20]. In addition, SDF-1 has been implicated in integrin-mediated adhesion in lung cancer and renal cancer cells [21-23]. SDF-1–mediated cell adhesion via ICAM-1 has also been reported in leukemia cells [24]. Firm cell adhesion between CD34+ cells and endothelial cells is reported to occur when ICAM-1 and SDF-1 are co-immobilized [25]. However, it is not clear whether the regulation of ICAM-1 expression and cell adhesion are mediated by SDF-1 in colorectal cancer cells.

Mitogen-activated protein kinases (MAPKs) are known as major signaling pathways that play an essential role in the development of inflammation and cancer [26]. Furthermore, they have been reported to be involved in cancer cell pathological functions, including invasion and angiogenesis [27]. In the present study, we show that SDF-1 induces ICAM-1 expression in colorectal cancer DLD-1 cells. Our data indicate that the SDF-1-induced increase of ICAM-1 expression and cell adhesion is mediated through the ERK, JNK and p38 intracellular signaling cascades, and the transcription factors Sp1, C/EBP-β and NF-κB. Our findings provide evidence of the molecular mechanisms by which SDF-1 induces ICAM-1 expression in colorectal cancer cells.

Methods

Materials

All culture materials were purchased from Gibco (Grand Island, NY, USA). PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), and SB203580 (p38 inhibitor) were purchased from Calbiochem (La Jolla, CA). Polyclonal anti-ICAM-1 and anti-CXCR4 neutralizing antibody were obtained from R & D Systems (Minneapolis, MN). Mouse monoclonal antibodies (mAbs) against ERK2, JNK1, phospho-ERK1/2, phospho-JNK1/2, NF-κB p65, Sp1, and C/EBP-β were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal antibodies against p38 and mouse monoclonal phospho-p38 antibody were purchased from Cell Signaling Technology (Beverly, MA). ERK, JNK, and p38 shRNA and control shRNA (scrambled negative control containing random DNA sequences) were purchased from the National RNAi Core Facility in Academic Sinica, Taipei, Taiwan. The NF-κB p65, Sp1, and C/EBP-β-siRNA and control siRNA (scrambled negative control containing random DNA sequences) were purchased from Invitrogen (Carlsbad, CA). AMD3100 (CXCR4 inhibitor) and all other chemicals of a reagent grade were obtained from Sigma (St. Louis, MO).

Cell culture

The colon cancer DLD-1 and SW48 cell lines were purchased from the Bioresources Collection and Research Center (BCRC) of the Food Industry Research and Development Institute (Hsinchu, Taiwan). Cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in a CO2 incubator at 37°C. Human umbilical vein endothelial cells (HUVECs) were isolated by collagenase digestion. Briefly, human umbilical cords were washed, filled with 0.1% collagenase, and incubated at 37°C for 10 min. The suspension of ECs collected was centrifuged for 10 min at 1200 × g. The pellet was resuspended in M199 supplemented with penicillin/streptomycin and 20% FBS, after which the cells were plated onto cell culture dishes. Cultures were maintained at 37°C in a humidified atmosphere containing 5% CO2. HUVECs of passage 2 were used for experiments.

Flow cytometry analysis

The expressions of CXCR4 and ICAM-1 on the surface of DLD-1 cells were measured by indirect immunofluorescence using flow cytometry and the mouse monoclonal antibody (20 μg/mL; R&D) against CXCR4 and ICAM-1 [28].

Cell adhesion assay

Adherence of DLD-1 and SW48 cells to HUVECs was determined as described previously [29]. Before the adhesion experiments, cells were cultured in low-serum medium (0.5% FBS) for 12 h and then treated with SDF-1 (10 ng/mL) for 4 h and labeled with 1, 10-dioctadecyl-3, 3, 30, 30-tetramethylindocarbocyanine (DiI; Molecular Probes, Eugene, OR) for 20 min. The labeled cells
(2 × 10^5 cells/mL) were added to HUVECs and incubated for 1 h. In parallel experiments, DLD-1 cells were treated with specific inhibitors or transfected with specific shRNAs during SDF-1 stimulation. Non-adherent cells were removed by washing with PBS. The adherent cancer cells on the EC surface were identified and counted in 10 randomly selected microscopic fields (1.37 mm × 1.07 mm) under a Nikon Ti-E inverted epifluorescence microscope with ×10 objective, and the adhesion was expressed as a multiple compared to the controls. To determine the role of CXCR4 and ICAM-1 in the adhesion of DLD-1 and SW48 cells to HUVECs, CRC cells were pre-incubated with 20 μg/mL of anti-human CXCR4 and ICAM-1 antibodies (R&D) for 30 min, pretreated with AMD3100, or transfected with the ICAM-1 siRNA prior to the adhesion assay.

**Real-time quantitative PCR**

Real-time PCR of three transcripts was performed using an ABI Prism 7900HT with the FastStart DNA SYBR Green I kit (Roche). The designed primers in this study were: ICAM-1 forward primer, 5′-GTGAC ATGCA GCACC TCTCTG-3′; ICAM-1 reverse primer, 5′-TCCAT GTGTA TCTCT CCTCA-3′; 18S rRNA forward primer, 5′-CGGCC AGACG CCATT CGGAAC-3′, 18S rRNA reverse primer, 5′-GAA TC GAACC CTGAT TCCCC GTCTC-3′. Quantification was performed using the 2^-ΔΔCt method [30]. All samples were measured in duplicate. The average value of both duplicates was used as the quantitative value.

**ELISA for cell surface ICAM-1 expression**

ICAM-1 expression on the cancer cell surface was measured by cell surface ELISA as previously described [29]. Briefly, DLD-1 cells cultured in 96-well plates were fixed by 4% paraformaldehyde. Cell surface ICAM-1 expression was assessed using the mouse anti-human ICAM-1 mAb, followed by a horseradish-peroxidase-conjugated secondary antibody. The absorbance of each well was measured at 490 nm after the reactions were stopped.

**Western blot analysis**

Samples were lysed with a buffer containing 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and a protease inhibitor mixture (PMSF, aprotinin and sodium orthovanadate). Protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Equal amounts of total proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) (10% running, 4% stacking), transferred onto a nitrocellulose membrane, and analyzed using the designated antibodies and the Western-Light chemiluminescent detection system (Bio-Rad).

**shRNA and siRNA transfection**

For shRNA transfection, DLD-1 cells were transfected with the designated MAPK shRNA plasmids by using shRNA plasmid transfection reagent (Santa Cruz). For siRNA transfection, DLD-1 cells were transfected with the specific NF-κB p65, Sp1-1, and C/EBP-β-siRNA or control siRNA by using an RNAiMAX transfection kit (Invitrogen).

**Luciferase assays**

Human ICAM-1 promoter constructs containing -537/+16, -413/+16, -323/+16, -245/+16, -134/+16, and -88/+16 of ICAM-1 5′-flanking DNA linked to the firefly luciferase reporter gene of plasmid pGL4 (Promega, Madison, WI) were used. DNA plasmids at a concentration of 1 mg/ml were transfected into DLD-1 cells by Lipofectamine (Gibco). The pSV-β-galactosidase plasmid was cotransfected to normalize the transfection efficiency. Values obtained were normalized to the levels of β-galactosidase in the cell lysates. β-galactosidase activities were determined with an assay kit and exhibited <20% variation between samples.

**Transcription factor assays (TF ELISA assays)**

Nuclear extracts of cells were prepared by nuclear protein extract kits (Panomics, Redwood City, CA). Equal amounts of nuclear proteins were used for quantitative measurements of NF-κB p65, Sp1 and C/EPB-β activation using commercially available ELISA kits (Panomics).

**Chromatin immunoprecipitation assay (ChIP)**

After cross-linking with 1% formaldehyde, the cells were centrifuged and then resuspended in a lysis buffer for three times of sonication of 15 sec each. Supernatants were recovered by centrifugation. Aliquots of the pre-cleared sheared chromatin were then immunoprecipitated using 2 μg antibodies against IgG, NF-κB p65, Sp1 and C/EPB-β. The resulting DNA was used for PCR analysis, and the amplified DNA fragments were visualized on an agarose gel. The human ICAM-1 promoter region −305/−91 was amplified with the PCR primer pairs 5′-ACCTT AGCGC GGTGT AGACC-3′ and 5′-CTCCG GAACA AATGC TGC-3′.

**Statistical analysis**

The results are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was determined using an independent Student t-test for two groups of data and analysis of variance (ANOVA) followed by Scheffe’s test for multiple comparisons. P values less than 0.05 were considered significant.
Results
Effect of SDF-1 on adhesion of CRC cells to HUVECs
In order to quantify the adhesion of the CRC cells to HUVECs, DLD-1 and SW48 cells were treated with different doses of SDF-1 (0–50 ng/mL) for 4 h and then labeled with DiI. The labeled cells were seeded onto the HUVEC monolayers and co-cultured for 1 h. After removal of the non-adherent cells, the remaining adherent cells were evaluated. SDF-1 stimulation induced increased adherence of DLD-1 and SW48 cells to HUVECs in a dose-dependent manner (Figure 1A). To assess the role of CXCR4 in SDF-1-induced cell adhesion in DLD-1 and SW48 cells, we evaluated the effect of CXCR4 inhibitor AMD3100 (100 nM) and CXCR4 neutralizing antibody on SDF-1-induced cell adhesion. Pretreatment of AMD3100 and neutralizing antibody against CXCR4 significantly inhibited the adhesion of DLD-1 and SW48 cells to HUVECs (Figure 1B).

Pretreatment with AMD3100 could also inhibit adhesion of DLD-1 cells treated with different doses of SDF-1 (Figure 1C). The effect of SDF-1 on CXCR4 expression in DLD-1 cells was evaluated by flow cytometry assay using CXCR4 antibody. As shown in Figure 1D, CXCR4 is hardly expressed in DLD-1 cells, but cell surface expression is up-regulated by stimulation with SDF-1 for 4 h in DLD-1 cells.

Effect of SDF-1-induced ICAM-1 expression on adhesion of DLD-1 cells to HUVECs
To investigate the role of ICAM-1 in the adhesion of DLD-1 and SW48 cells to HUVECs, we blocked the ICAM-1 function by using ICAM-1 neutralizing antibody and specific siRNA. SDF-1-induced adhesion of DLD-1 and SW48 cells to HUVECs was significantly inhibited by cells incubated with ICAM-1 neutralizing antibody, or transfected with ICAM-1 siRNA, suggesting a direct involvement of ICAM-1 in the adhesive interaction between CRC cells and HUVECs (Figure 2A). To assess the role of CXCR4 in SDF-1-induced ICAM-1 expression in DLD-1 and SW48 cells, we evaluated the effect of AMD3100 (100 nM) and CXCR4 neutralizing antibody on SDF-1-induced ICAM-1 expression. Pretreatment of...
AMD3100 and neutralizing antibody against CXCR4 markedly inhibited the expression of ICAM-1 mRNA (Figure 2B). Pretreatment with AMD3100 could also inhibit ICAM-1 expression of DLD-1 cells treated with different doses of SDF-1 (Figure 2C). The basal level of ICAM-1 expression in DLD-1 cells was evaluated by flow cytometry, as shown in Figure 2D.

**SDF-1-induced ICAM-1 expression in DLD-1 and SW48 cells is dose- and time-dependent**

Next, we examined the effect of SDF-1 on the ICAM-1 mRNA and cell surface protein expression by CRC DLD-1 and SW48 cells. Cells were stimulated with SDF-1 (10 ng/mL) for the times indicated, or at different doses (0–50 ng/mL) for 4 h. The changes in ICAM-1 expression compared with the control cells at the same time points were analyzed by real-time PCR, and cell surface ICAM-1 expression was detected by ELISA. The ICAM-1 mRNA level began to increase after 1 h of SDF-1 treatment and reached its highest level at 4 h (Figure 3A). The cell surface ICAM-1 expression of DLD-1 and SW48 cells also increased after 4 h of SDF-1 stimulation (Figure 3B). The induction of ICAM-1 mRNA and cell surface protein expression by SDF-1 stimulation was dose-dependent (Figure 3C and 3D). In addition, SDF-1 also induced an increase in total ICAM-1 protein expression in DLD-1 cells in a time-dependent manner (Figure 3E).

ICAM-1 expression in the indicated times was inhibited by DLD-1 cells treated with AMD3100 (Figure 3F). In addition, SDF-1 induced only slight increases in the DLD-1 VCAM-1 transcript level compared with untreated cells (Figure 3G).

**Effect of MAPK inhibitors on ICAM-1 mRNA expression and cell adhesion in DLD-1 cells**

To determine whether the SDF-1-induced ICAM-1 expression and cell adhesion to HUVECs is mediated through the MAPK-dependent pathway, DLD-1 cells were incubated with the specific inhibitor for ERK (PD98059; 30 μM), JNK (SP600125; 20 μM), or p38 (SB203580; 10 μM) for 1 h before and during stimulation with SDF-1. The SDF-1-induced ICAM-1 mRNA
expression in DLD-1 cells (Figure 4B) and cell adhesion to HUVECs (Figure 4C) was significantly inhibited by PD98059, SP600125 and SB203580. To further confirm the involvement of ERK, JNK, and p38, in the modulation of ICAM-1 expression through SDF-1 stimulation, we examined the effects of the specific shRNAs of these signaling pathways on SDF-1-induced ICAM-1 expression in DLD-1 cells. The effectiveness of the silencing was validated because ERK-, JNK-, and p38-shRNAs (compared with control shRNA) caused an 85% reduction in ERK, JNK, and p38 protein expressions, respectively (Figure 4A). The SDF-1-induced ICAM-1 mRNA (Figure 4B) and cell surface ICAM-1 (Figure 4C) were inhibited by transfection with ERK-, JNK-, and p38-shRNAs. Furthermore, SDF-1-induced total ICAM-1 protein expression in DLD-1 cells was also inhibited by cells pretreated with PD98059, SP600125 and SB203580 (Figure 4D).

Our previous study demonstrated that the phosphorylation level of p38 in DLD-1 cells increased rapidly after stimulation by SDF-1 [20]. In the present study, the phosphorylation of ERK, JNK and p38 in DLD-1 cells also increased after SDF-1 stimulation (Figure 4E). In addition, the SDF-1–induced phosphorylation of ERK, JNK and p38 in DLD-1 cells was inhibited by cells pretreated with AMD3100 (Figure 4E).

Sp1, C/EBP and NF-κB are essential for the SDF-1–induction of human ICAM-1 expression

To identify the cis-acting elements in the ICAM-1 gene promoter that mediate SDF-1-induced ICAM-1 transcription, luciferase assays were conducted with the ICAM-1 p537-Luc plasmid and several deletion promoter constructs (Figure 5). In DLD-1 cells, the −537/+16 region of ICAM-1 directed maximum luciferase activity. Sequence deletion from −245 to −134 caused the

Figure 3 Induction of ICAM-1 expression in DLD-1 and SW48 cells by SDF-1 stimulation. Samples were isolated at the indicated time periods or doses. All bar graphs represent multiple increases of control cells (CL) normalized to 18S rRNA by real-time PCR analysis (A, C). The cell surface ICAM-1 protein expression levels were determined by cell surface ELISA analyses (B, D). DLD-1 and SW48 cells were stimulated with 10 ng/mL SDF-1 for the times indicated (A, B), or stimulated with SDF-1 at various doses for 4 h (C, D). Data are shown as mean ± SEM. *P < 0.05 versus CL DLD-1 cells. (E) The expression of total ICAM-1 in DLD-1 cell lysate after SDF-1 stimulation for the times indicated was determined using Western blotting. (F) Before being kept as CL, cells were pretreated with AMD3100 for 1 h and were then stimulated with SDF-1 for the times indicated. *p < 0.05 versus CL. #p < 0.05 versus DMSO-treated cells. (G) DLD-1 cells were stimulated with SDF-1 for the times indicated. The VCAM-1 mRNA expression level was determined by real-time PCR analysis normalized to 18S rRNA.
luciferase activity to decrease to ~85%; and 5'-deletion to ~88 nearly eliminated the activity (Figure 5).

To investigate whether SDF-1 can activate Sp1, C/EBP-β, and NF-κB in DLD-1 cells, we performed quantitative analysis of the Sp1, C/EBP-β, and NF-κB p65 binding activities in vitro using TF ELISA kits from Panomics. The treatment of DLD-1 cells with SDF-1 caused Sp1, C/EBP-β, and NF-κB p65 binding activities to increase after 1 h and remain elevated for at least 2 hours.

We further tested whether Sp1, C/EBP-β, and NF-κB activation are involved in the signal transduction pathway leading to the SDF-1 induction of ICAM-1 promoter activity. DLD-1 cells were transfected with siRNAs for Sp1, C/EBP-β, or p65 followed by stimulation with SDF-1 for 4 h. The Sp1, C/EBP-β, and NF-κB p65-specific siRNAs (compared with control siRNA) caused an 80% reduction in Sp1, C/EBP-β, and NF-κB p65 protein expressions, respectively (Figure 6D). The SDF-1-induced ICAM-1 p537-Luc promoter activity levels (Figure 6E) were significantly down-regulated by the inhibition of specific siRNAs, indicating that Sp1, C/EBP-β, and p65 are involved in the regulation of ICAM-1 gene expression. These results were confirmed by ChIP analysis. Immunoprecipitated chromosomal DNA with Sp1, C/EBP-β, and NF-κB was subjected to PCR, using primers designed to amplify the ICAM-1 promoter region harboring these transcription factor binding sites. Sp1, C/EBP-β and NF-κB were indeed found to bind the ICAM-1 promoter region (Figure 6F).
Figure 6 Sp1-, C/EBP-β- and NF-κB-DNA binding activities induced by SDF-1 stimulation in DLD-1 cells. (A) Sp1 activation, (B) C/EBP-β activation and (C) NF-κB p65 activation were determined by a TF ELISA assay. (D) The gene silencing efficiency of 48-h transfection of siRNA on Sp1, C/EBP-β, and p65 protein levels of DLD-1 cells. After 48 h of transfection, protein was isolated and the Sp1, C/EBP-β, and p65 expression was analyzed by Western blotting. (E) ICAM-1 mRNA and p537-Luc activity were determined in DLD-1 cells transfected with control siRNA (si-CL), si-Sp1, si-C/EBP-β, or si-p65, and then stimulated with 10 ng/mL SDF-1 for 4 h. All bar graphs represent folds of CL DLD-1 cells, mean ± SEM. *P < 0.05 versus CL. †P < 0.05 versus si-CL with SDF-1 stimulation. (F) ChIP assays were performed for Sp1, C/EBP-β, and NF-κB using p65 antibodies.
MAPK signaling pathways were involved in SDF-1-induced ICAM-1 promoter activity

To evaluate whether the inhibition of ICAM-1 expression by MAPK signaling pathways occurs at the transcriptional level, we studied the effects of MAPK inhibitors and shRNAs on SDF-1-induced ICAM-1 p537-Luc promoter activity. Treatment of SDF-1 increased the luciferase activity compared with the unstimulated cells after normalization through transfection control (Figure 7A). Pretreatment of cells with PD98059, SP600125 and SB203580, or ERK-, JNK-, p38-shRNA resulted in a marked inhibition of the SDF-1-induced ICAM-1 promoter activity (Figure 7A).

To explore whether MAPKs activate the promoter leading to ICAM-1 transcription via activations of Sp1, C/EBP-β, and NF-kB, DLD-1 cells were pretreated with MAPK inhibitors or transfected with MAPK shRNAs followed by the SDF-1 treatment. The Sp1, C/EBP-β, and NF-kB p65 activations were assessed using TF ELISA kits. Pretreatment of cells with PD98059, SP600125 and SB203580, or transfected with ERK-, JNK-, and p38-shRNA significantly inhibited the SDF-1-induced Sp1- (Figure 7B) and NF-kB p65-DNA (Figure 7D) binding activity, whereas pretreatment of cells with PD98059 and SB203580, or transfected with ERK- and p38-shRNA markedly inhibited the SDF-1-induced C/EBP-β-DNA binding activity (Figure 7C). In addition, as shown in Figure 7E, SDF-1 also induced degradation of IκB protein in DLD-1 cells in a time-dependent manner.

Discussion

The cell adhesion process plays a key role in tumor progression. Several adhesion molecules, including ICAM-1, have been implicated in the tumor transformation and metastasis via the mediating adhesion of cancer cells to the vascular endothelium. This is an important procedure for executing the subsequent steps of invasion and survival of cancer cells [31]. It has been shown that CRC metastases are related to the ability of cancer cells to adhere to the microvascular endothelium of the lung that expresses the ligands for ICAM-1 on the tumor cell

![Figure 7 MAPK signaling pathways are involved in SDF-1-induced ICAM-1 promoter activity.](image-url)
The expression of SDF-1 has been detected in several cancer cells, indicating that these pathways may be important in the metastasis of tumor cells [35,36]. SDF-1 is a constitutively expressed and inducible chemokine that modulates biological and physiological processes, including embryonic development and organ homeostasis [37]. Abnormal expression of SDF-1 has been detected in various solid tumor tissues such as ovarian cancer [38], breast cancer [39] and colorectal cancer [40]. SDF-1 has been shown to promote the growth, invasion and metastasis of CRC cells [41], implying that SDF-1 plays a role in the progression of CRC; however, the mechanisms of how SDF-1 stimulates metastasis of CRC cells are not totally understood. In this study, we evaluated the molecular mechanisms underlying the roles of SDF-1 in modulating ICAM-1 expression and cell adhesion to HUVECs in colon cancer cells. Our results have demonstrated that SDF-1-induced expression of ICAM-1 expression is mediated by the MAPKs, and downstream Sp1, C/EBP-β and NF-κB signaling pathways.

The promoter region of the ICAM-1 gene has different binding sites for various transcriptional factors [42]. Previous studies have shown that the transcription factors NF-κB, Sp1 and C/EBP-β can be activated through the MAPK pathways in colorectal cancer cells [20,43,44]. Regulation of gene expression through the use of combinations of different transcription factors has been observed [45,46]. It has been reported that NF-κB and Sp1 can be activated by MAPK family members, depending on the target gene in different cells [47]. Patel et al. reported that MAPKs mediate NF-κB and C/EBP-β activation, which leads to the transcription of specific genes [48]. To evaluate the signaling factors upstream of the activation of NF-κB, Sp1 and C/EBP-β that lead to ICAM-1 transcriptional activation in DLD-1 cells, we investigated the role of MAPKs using specific inhibitors. In addition, we performed TF ELISA assays to demonstrate that the regulation of ICAM-1 gene expression in DLD-1 cells was mediated by increased NF-κB p65, Sp1- and C/EBP-β-DNA binding activities. Based on our results, we propose a possible signal transduction pathway in DLD-1 cells in which SDF-1 induces ERK, JNK and p38 phosphorylation, which activates NF-κB, Sp1 and C/EBP-β to lead to their binding to respective sites in the ICAM-1 promoter, thus resulting in ICAM-1 transcriptional activation.

Several studies have indicated that CRC cells express CXCR4 and CXCR7, the receptors for SDF-1, and that their survival and migration to distant tissues are promoted by SDF-1 [41,49]. The binding of SDF-1 to CXCR4 may affect several signaling pathways, which can lead to multiple responses. Our previous study revealed that the expression of urokinase plasminogen activator in CRC DLD-1 cells by SDF-1 stimulation is mediated by CXCR4 [20]. In order to analyze the role of CXCR4 in ICAM-1 expression in human CRC cells, we evaluated the effect of CXCR4 function-blocking antibody on SDF-1-induced ICAM-1 expression. Our results suggest that when DLD-1 cells encounter an external stimulus of SDF-1, SDF-1 induces ICAM-1 expression via CXCR4 up-regulation. Interestingly, DLD-1 cells did not express surface CXCR4 [50], but they had abundant CXCR4 after SDF-1 stimulation, as determined by flow cytometry. Up-regulation of CXCR4 cells is functionally important, as SDF-1-stimulated DLD-1 cells in contrast to control cells respond to SDF-1 by inducing the ICAM-1 expression and adhering to HUVECs in response to SDF-1. Previously it had been reported that CXCR4 surface expression is hardly detectable on neutrophils, but expression became apparent gradually after incubation [51]. An alternative possibility described recently postulates that CXCR7 may serve as a co-receptor for CXCR4 and mediate SDF-1-induced intracellular signaling [52]. Several studies have indicated that CRC cells also express CXCR7, the receptors for SDF-1, and that their survival and migration to distant tissues is promoted by SDF-1 [53]. However, the mechanisms of CXCR4 expression in DLD-1 cells and the interaction between CXCR7 remains unknown, and further study is required to identify whether SDF-1 affects CXCR7 function and CXCR4 expression in CRC cells.

ICAM-1 expression modulates several cell functions and processes that regulate the progression of malignancies, including apoptosis, cell motility, invasion and angiogenesis. It has been shown that ICAM-1 may support mesothelial adhesion of CRC cells [11]. Interaction of ICAM-1 on vascular or lymphatic endothelial cells has been found to promote the adhesion of lung cancer and breast cancer cells [54,55]. In addition, ICAM-1 may be expressed by cancer cells themselves and contribute to their invasiveness [56].
Conclusions
In summary, our data contribute new information about the mechanisms by which SDF-1 induces ICAM-1 expression and cell adhesion to the endothelium in colon cancer cells.

Abbreviations
CRC: Colorectal cancer; CXCL12: CXC chemokine ligand 12; SDF-1: Stromal cell-derived factor; CXCR4: CXC receptor 4; ICAM-1: Intercellular adhesion molecule-1; MAPKs: Mitogen-activated protein kinases; HUVEC: Human umbilical vein endothelial cells; ChIP: Chromatin immunoprecipitation assay.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
S-YT and C-NC designed research; S-YT, S-FC, M-HC, W-SH, Y-YH, and C-HS performed research; S-YT, S-FC and C-NC analyzed data; and H-CK and C-NC wrote the paper. All authors read and approved the final manuscript.

Acknowledgement
This work was supported by Chang Gung Memorial Hospital and Chang Gung Institute of Technology Chiayi Campus (grants CZRPg80253, CMRPg690171, CMRPGA0061, CMRPGA0011, CMRPF680052 and EZRPF390261).

Author details
1Department of Hepato-Gastroenterology, Chang Gung Memorial Hospital, Chia-yi, Taiwan. 2Biophotonics & Molecular Imaging Research Center, National Yang Ming University, Taipei, Taiwan. 3Department of Biochemical Science and Technology, National Chia-Yi University, Chia-yi, Taiwan. 4Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Chia-yi, Taiwan. 5Department of Nursing, Chang Gung University of Science and Technology; Chronic Diseases and Health Promotion Research Center, CGUST, Chia-yi, Taiwan.

Received: 30 July 2012 Accepted: 22 October 2012
Published: 25 October 2012

Reference
1. Gallagher DJ, Kemeny N: Metastatic colorectal cancer: from improved survival to potential cure. Oncology 2010, 78:237–248.

2. Strier RM: Chemokines: not just leukocyte chemotactants in the promotion of cancer. Nat Immunol 2001, 2:285–286.

3. Vandercappellen J, Van Damme J, Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett 2006, 262:226–244.

4. Burger JA, Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761–1767.

5. Teicher BA, Fricker SP: CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927–2931.

6. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, Moons L, Wei S, Zou L, Machelon V, Emilie D, Terrassa M, Lackner A, Curiel TJ, Carmeliet P, Zou W: CXCL12 and vascular endothelial growth factor synergistically induce neangiogenesis in human ovarian cancers. Cancer Res 2005, 65:465–472.

7. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, Beider K, Avniel S, Kasem S, Galun E, Peled A: Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004, 18:1240–1242.

8. Ottaviano A, Franco R, Akkio Talamanc A, Liguori G, Tatangelo F, Delrio P, Nasti G, Barletta E, Facchin G, Daniele B, Di Blasi A, Napolitano M, Ierano C, Calemma R, Leonardi E, Altino V, De Angelis V, Falanga M, Boccia V, Capuozzo M, Parisi V, Botti G, Castello G, Vincenzo Iaffaioli R, Scala S: Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006, 12:2795–2803.

9. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Blichak AJ, Hoon DS: Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005, 23:2744–2753.

10. Paschos KA, Canovas D, Bird NC: The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 2009, 21:665–674.

11. Kisacek K, Mikula-Pietraski J, Catar R, Dworacki G, Winckiewicz M, Frydchochowicz M, Dragun D, Staniszewski R, Jories A, Witowski J: Oxidative stress-dependent increase in ICAM-1 expression promotes adhesion of colorectal and pancreatic cancers to the senescent peritoneal mesothelium. Int J Cancer 2010, 127:293–303.

12. Arteia B, Lassen U, Lopategui A, Svennbjörnsen B, Smidsrud B, Vital-David A, Vanaclocha F: Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antimtumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology 2010, 51:2172–2182.

13. Boyano MD, García-Vázquez MD, López-Micheleña T, Gardeazabal J, Bilbao J, Cahavate ML, Galdeano AG, Izu R, Díaz-Ramón L, Raton JA, Díaz-Pérez JL: Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. Br J Cancer 2000, 83:847–852.

14. Alexiou D, Katayannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Brias I, Tsigis C: Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 2001, 37:2392–2397.

15. Dymicka-Piekanska V, Kemona H: Does colorectal cancer clinical advancement affect adhesion molecules (α6β3, E-selectin, S-E-selectin and ICAM-1) concentration? Tumori Res 2009, 124:80–83.

16. Hayes SH, Seigel GM: Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol 2009, 2:553–560.

17. Taglia L, Matsuiski D, Markowski KA, Benia RV: Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase. Am J Physiol Gastrointest Liver Physiol 2007, 292:G182–G190.

18. Gulubova MV: Expression of cell adhesion molecules, their ligands and tumour necrosis factor in the liver of patients with metastatic gastrointestinal carcinomas. Histochim J 2002, 3467–77.

19. Yadav VR, Prasad S, Sung B, Gelovani JG, Guha S, Krishnan S, Aggarwal BB: Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer 2012, 130:2176–2784.

20. Huang WS, Chin CC, Chen CN, Kuo YH, Chen TC, Yu HR, Tung SY, Chen CH, Hsieh YY, Guo SE, Shi CS, Liu TJ, Kuo HC: Stromal cell-derived factor-1/CXCR4 receptor and β1 integrin interaction regulates urokinase-type plasminogen activator expression in human colorectal cancer cells. J Cell Physiol 2012, 227:1114–1122.

21. Hartmann TN, Burger JA, Glokde A, Fuji N, Burger M: CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005, 24:4462–4471.

22. Burger M, Glokde A, Hartmann T, Schmitt-Gräff A, Silberstein LE, Fuji N, Kipps TJ, Burger JA: Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 2003, 22:8093–8101.

23. Jones C, Marian D, Weich E, Engl T, Wedel S, Relja B, Jonas D, Blaheta RA: CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res 2007, 313:4051–4065.

24. Chen YY, Malik M, Tomkowitz BE, Collman RG, Prasans A: BCR-ABL1 alters SDF-1-mediated adhesive responses through the β2 integrin LFA-1 in leukemia cells. Blood 2008, 111:5182–5186.

25. Peled A, Grabovskys V, Habler J, Sandbank J, Arena-Seisedos F, Pettit L, Ben-Hur L, Lapidot T, Alon R: The chemokine SDF-1 stimulates integrin-mediated arrest of CD34+ cells on vascular endothelium under shear flow. J Clin Invest 1999, 104:1199–1211.

26. Aitt A, Schaller M: Role of the immediate early response 3 (IER3) gene in cellular stress response, inflammation and tumorigenesis. Eur J Cell Biol 2011, 90:545–552.

27. Zhu C, QX, Chen Y, Sun B, Dai Y, Gu Y: P3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 2011, 137:1587–1594.

28. Chen CN, Chang SF, Lee PL, Chang K, Chen LJ, Usami S, Chen S, Chiu JJ: Neutrophils, lymphocytes, and monocytes exhibit diverse behaviors in...
transendothelial and subendothelial migrations under coculture with smooth muscle cells in disturbed flow. *Blood* 2006, 107:1933–1942.

29. Chen TC, Chien SJ, Kuo HC, Huang WS, Sheen JM, Lin TH, Yen CK, Sung ML, Chen CN: High glucose-treated macrophages augment E-selectin expression in endothelial cells. *J Biol Chem* 2011, 286:25564–25573.

30. Yeh CC, Chang H, Chiang JK, Tsai WT, Chen LM, Wu GF, Chen S, Chen CN: Regulation of plasminogen activator inhibitor-1 expression in osteoarthritic chondrocytes by fluid shear stress: role of PKCα. *Arthritis Rheum* 2009, 60:2350–2361.

31. Kobayashi H, Boelte KC, Lin PC: Endothelial cell adhesion molecules and cancer progression. *Curr Med Chem* 2007, 14:377–386.

32. ten Kate M, Hofland LJ, van Grevenstein WM, van Koetsveld PV, Jeekel J, van Eijck CH: Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. *Int J Cancer* 2004, 112:943–950.

33. Kang X, Wang F, Xie JD, Cao J, Xian PZ. Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer. *World J Gastroenterol* 2005, 11:4250–4253.

34. Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, Ohira M, Ishikawa T, Hirakawa-YS Chung K: Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. *Clin Exp Med* 2004, 5:5074–5089.

35. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I: Chemokine receptor CXCR7 promotes cell migration and tumor cell invasion through Erk1/2-NF-κB- and RNA polymerase II binding to the CXCL12 enhancer. *FEBS J* 2008, 275:5074–5089.

36. Chu CY, Cha ST, Lin WC, Lu PH, Tan CT, Chang CC, Lin BR, Jee SH, Kuo ML: Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. *PLoS One* 2011, 6:e27399.

37. Kawada K, Hosogi H, Soshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M, Taketo MM: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. *Oncogene* 2007, 26:4679–4688.

38. Bühler H, Cohen CD, Linder S, Kretzler M, Schülendorff D, Mack M: Post-translational and cell type-specific regulation of CXCR4 expression by cytokines. *Eur J Immunol* 2003, 33:3028–3037.

39. Levoye A, Balabanian K, Baleux F, Bachelet F, Lagane B: CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. *Blood* 2009, 113:6085–6093.

40. Burns JM, Summers BC, Wang Y, Melkian A, Beraiovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K, Howard MC, Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. *J Exp Med* 2006, 203:2201–2213.

41. Finkel AH, Reininger AJ, Bode PA, Wurzinger LJ: ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells. *Clin Exp Metastasis* 2004, 21:185–189.

42. Kawai Y, Kaidoh M, Yokoyama S, Sano K, Ohashi T: Chemokine CCL2 facilitates ICAM-1-mediated interactions of cancer cells and lymphatic endothelial cells in sentinel lymph nodes. *Cancer Sci* 2009, 100:419–428.

43. Roland CL, Kraken AH, Sarr MG, Barnett CC Jr: ICAM-1 expression determines malignant potential of cancer. *Surgery* 2007, 141:705–707.